REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Extended GH Stack

GH Optimizationadvanced

91

synergy

91
Peptides

3

Avg Daily mcg

650

Level

advanced

Added

May 17, 2026

Overview

The Extended GH Stack adds IGF-1 LR3 to the classic CJC-1295 + Ipamorelin base, creating a three-tier growth hormone axis protocol that addresses GH secretion, GH release, and downstream IGF-1 signaling simultaneously. CJC-1295 and Ipamorelin handle the upstream signaling — increasing GH output through GHRH and ghrelin pathways respectively. IGF-1 LR3 (a long-acting analog of Insulin-like Growth Factor-1) enters downstream, acting directly on muscle, bone, and organ cells to drive protein synthesis, cellular hypertrophy, and tissue growth — the actual anabolic outcomes that elevated GH is designed to produce. The practical advantage of adding IGF-1 LR3 is ensuring the anabolic signal reaches peripheral tissue even when natural liver conversion of GH to IGF-1 is suboptimal — common with age, metabolic dysfunction, or intensive training loads. IGF-1 LR3 has a 20–30 hour half-life compared to native IGF-1''s minutes, providing sustained receptor activation throughout the day. This stack is for experienced users who have established a response to the classic GH stack and want to extend its downstream effects. IGF-1 LR3 is administered post-workout to direct its anabolic action toward recently trained muscle tissue. This protocol requires blood work monitoring of IGF-1 levels (often quarterly), fasting glucose, and HbA1c due to IGF-1''s insulin-like effects on glucose metabolism.

Dosing Protocol

CJC-1295

Every day· subcutaneous

300 mcg

per dose

Ipamorelin

Every day· subcutaneous

300 mcg

per dose

IGF-1 LR3

daily (post-workout)· subcutaneous

50 mcg

per dose

Goals & Evidence

Maximum anabolismMuscle hypertrophyGH axis optimizationPerformance
Evidence tier:Human Data

Warnings

  • IGF-1 LR3 carries significant risk if IGF-1 levels are not monitored. Contraindicated with any cancer history. Requires medical supervision.

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.